Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians

Sahu, Kamal Kant; Jindal, Vishal; Siddiqui, Ahmad Daniyal; Černý, Jan

doi:10.1016/j.bcmd.2020.102439

Cited by 23 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients suffering from cancer are at higher risk of acquiring viral infections like SARS-CoV-2 infection and are likely to develop more complications [64,65]. Patients with hematological malignancies, patients on active chemotherapy, neutropenic patients, and bone marrow transplant patients are significantly at a higher risk [66]. Almost all major cancer centers and oncology experts have issued their respective guidelines and statements for their practicing oncologists, nurse practitioners, cancer patients, and their care providers.…”

Section: Cancer Patients and Their Carementioning

confidence: 99%

COVID-2019: update on epidemiology, disease spread and management

Sahu

Mishra

Lal

2020

Monaldi Arch Chest Dis

Self Cite

View full text Add to dashboard Cite

With each passing day, more cases of Coronavirus disease (COVID-2019) are being detected and unfortunately the fear of novel corona virus 2019 (2019-nCoV) becoming a pandemic disease has come true. Constant efforts at individual, national, and international level are being made in order to understand the genomics, hosts, modes of transmission and epidemiological link of nCoV-2019. As of now, whole genome sequence of the newly discovered coronavirus has already been decoded. Genomic characterization nCoV-2019 have shown close homology with batderived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. Structural analysis of the receptor binding site has confirmed that 2019-nCoV binds with the same ACE 2 receptor protein as human SARS virus. Compared to the previous coronavirus outbreaks, the overall mortality rate is relatively low for COVID-2019 (2-3%). Suspected cases must be quarantined till their test comes positive or they clear infection. At present, treatment of COVID-2019 is mostly based on the knowledge gained from the SARS and MERS outbreaks. Remdesivir, originally develop as a treatment for Ebola virus disease and Marburg virus infections, is being studied for its effectiveness against 2019-nCoV infection. Many other antiviral agents and vaccines are being tested but most of them are in phase I or II and hence unlikely to be of any benefit immediately with regards to current outbreak. Hence, the standard infection control techniques and preventive steps for healthy individuals and supportive care for the confirmed cases is the best available strategy to deal with current viral outbreak.

show abstract

Section: Cancer Patients and Their Carementioning

confidence: 99%

COVID-2019: update on epidemiology, disease spread and management

Sahu

Mishra

Lal

2020

Monaldi Arch Chest Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…The preliminary observations from China and Europe suggested that COVID-19 patients with cancer overall faced much higher morbidity and mortality. This has led to the initial wave of recommendations of delaying therapy cycles, switching to less myelosuppressive regimens, and delaying stem cell transplantations (and related immunosuppression) whenever clinically acceptable [ [125] , [126] , [127] ]. More recently single-institution studies seem to suggest however that immunosuppression and anti-cancer therapy can be delivered safely as long as aggressive non-pharmacological intervention (NPI) protocols are followed to prevent COVID-19 transmission.…”

Section: Immunosuppression In Hematological Malignanciesmentioning

confidence: 99%

A review on how to do hematology consults during COVID-19 pandemic

Sahu

Černý

2021

Blood Reviews

Self Cite

View full text Add to dashboard Cite

The ongoing COVID-19 pandemic is the most trending and talked topic across the World. From its point of origin in Wuhan, China to clinical laboratory at NIH, a mere six-month-old SARS-CoV-2 virus is keeping the clinicians, and scientists busy at various fronts. However, COVID-19 is an emerging and evolving disease and each day brings in more data, new figures, and findings from the field of clinical practice. The role of hematologists has been increasingly recognized during the current pandemic because of several reasons. Most important of them are the characteristic hematological findings of COVID-19 patients that also have prognostic implications and that were not seen in other viral infections. The treatment of hematological complications in COVID-19 patients is very challenging given the critical care setting. There are interim and limited guidelines thus far due to the novelty of the disease. As this remains to be a quite fluid situation, all the appropriate medical societies including the major hematology bodies are proposing initial and interim guidelines (e.g. ASH guideline). This puts a hematologist on consult service in a dubious position where, he/she must tailor the recommendations on case to case basis. The purpose of this review is to provide the background context about the impact of COVID-19 on the blood system and to summarize the current interim guidelines to manage the associated hematological issues in COVID-19 infection.

show abstract

“…On the other hand, transplant should be postponed until the patient has fully recovered with no symptoms left and has been tested with two negative subsequent PCR test at least 1 week apart. 21,27,28…”

Section: General Advice For Transplantation In MM Patientsmentioning

confidence: 99%

“…Travel if absolutely necessary only and by a private car when possible. Diagnostic procedures should follow local guidelines 21,28.…”

mentioning

confidence: 99%

Multiple Myeloma Management in COVID-19 Era

Kurniawan

Halim

Sutandyo

2021

ASJO

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has become a world pandemic since early 2020. The complexity of handling multiple myeloma (MM) has increased substantially during this pandemic. The objective of this review is to know the current recommendation to manage MM in the COVID-19 era. Methods Electronic databases, including PubMed central and PubMed, were used to conduct a literature search. It was conducted on May 18, 2020, using the keywords “multiple myeloma” AND “COVID-19” AND “Prevalence OR Impact OR treatment OR prophylactic.” The included articles were review articles, recommendations, case reports or series, or population-based studies (cross-sectional, cohort, case-control, or interventional), and full-text if available. Results A total of 124 articles were identified through the search strategy. The two reviewers screened titles and abstracts of all articles. Most articles were excluded because of ineligible to the criteria. Ultimately, 18 articles were included in the final evaluation. MM patients might have higher risk to become severe COVID-19 if they got infected due to their immunocompromised condition. Due to the pandemic, precise treatment priorities should be made by considering its benefit and the risk of MM progression. For the young, especially healthy patients, the most effective therapy should be offered and tailored to the patient’s goal. Several MM societies have published the recommendation regarding the special stage of MM. Conclusion Myeloma societies in the world have released recommendations related to the management of myeloma patients. However, there is scarce of evidence to do the recommendation.

show abstract

Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians

Cited by 23 publications

References 9 publications

COVID-2019: update on epidemiology, disease spread and management

COVID-2019: update on epidemiology, disease spread and management

A review on how to do hematology consults during COVID-19 pandemic

Multiple Myeloma Management in COVID-19 Era

Contact Info

Product

Resources

About